Revelation Biosciences, Inc.Revelation Biosciences, Inc.Revelation Biosciences, Inc.

Revelation Biosciences, Inc.

No trades
See on Supercharts
Market capitalization
‪3.56 M‬USD
55.2588USD
‪−120.25 K‬USD
‪1.63 M‬
Beta (1Y)
0.93

About Revelation Biosciences, Inc.

CEO
James M. Rolke
Headquarters
San Diego
Employees (FY)
9
Founded
2019
FIGI
BBG00Y646SC9
Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. Its product candidates include REVTx-99b, its lead therapeutic candidate being developed for allergic rhinitis and chronic nasal congestion, REVDx 501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation, and REVTx 200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. The company was founded on November 20, 2019 and is headquartered in San Diego, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.